Abstract
Introduction: It aimed to explore the effectiveness and safety of closed reduction and internal fixation (CRIF) and closed reduction and external fixation (CREF) in treating tibiofibular fracture, as well as their impact on patients’ bone metabolism and inflammatory responses.
Material and Method: A retrospective collection of 95 cases of tibiofibular fracture patients’ clinical data was conducted and the subjects were grouped: CRIF group (CRIFG) and CREF group (CREFG). Distinctions in clinical efficacy, visual analogue scale (VAS) scores, serum bone metabolism indicators, serum inflammatory cytokines, generic quality of life inventory-74 (GQOLI-74) scores, and adverse reactions (AR) were compared.
Result: The total clinical efficacy rates of the CRIFG and CREFG were 80.49% (33/41) and 85.19% (46/54), respectively(P >0.05). However, compared with the CRIFG, in the CREFG, the VAS scores were visibly reduced, and the GQOLI-74 scores in each dimension were visibly increased; serum osteocalcin (BGP),bone alkaline phosphatase (BALP), N-terminal propeptide of type 1 procollagen (P1NP)in the CREFG were visibly increased, while type I collagen carboxy terminal peptide β special sequence (β-CTX)was visibly decreased; C-reactive protein (CRP), interleukin-6 (IL-6), IL-1β, tumor necrosis factor-α (TNF-α)in the CREFG were visibly reduced; The total AR rates in the CRIFG and CREFG were 31.71% (13/41) and 18.52% (10/54), respectively(P <0.05).
Conclusion: CREF treatmentcan better alleviate patients’ pain levels, improve bone metabolism, reduce the degree of inflammatory response, and improve patients’ quality of life (QoL).
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.